Search Results for: covid-19
Articles
October 27, 2021
Ocugen, Inc. Announces Submission of IND to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate October 27, 2021
Ocugen, Inc. recently announced that it has submitted an Investigational New Drug application (IND) with the US FDA to evaluate the COVID-19 vaccine….
October 21, 2021
Pfizer & BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine October 21, 2021
Pfizer Inc. and BioNTech SE recently announced topline results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of...
October 14, 2021
TFF Pharmaceuticals & Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody Neutralizes SARS-CoV-2 Infection & Reduces Viral Load October 14, 2021
TFF Pharmaceuticals, Inc. and Augmenta Bioworks recently announced the publication of a research paper highlighting positive preclinical study results of...
October 4, 2021
HUMAN FACTORS STUDIES - Human Factors Studies During a Pandemic: How One Company Adapted to Covid-19 Restrictions October 4, 2021
Miranda Newbery says although it is possible to carry out use risk assessments, expert reviews and device comparisons – which do not require contact with end users – these cannot fully replace first-hand user feedback.
September 28, 2021
Soligenix Announces Accelerated Publication Demonstrating Efficacy & Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates September 28, 2021
Soligenix, Inc. recently announced publication of preclinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program) demonstrating durable broad-spectrum neutralizing...
September 21, 2021
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 September 21, 2021
ARCA biopharma, Inc. recently announced the first international patient has been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating...
September 8, 2021
Nature Medicine Publishes Positive Phase 3 Anakinra Study Results in Patients With COVID-19 Pneumonia September 8, 2021
Swedish Orphan Biovitrum AB (Sobi) and the Hellenic Institute for the Study of Sepsis recently announced that Nature Medicine has published positive results from the investigator-sponsored Phase 3….
September 8, 2021
AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction September 8, 2021
AIM ImmunoTech Inc. recently announced it has submitted a Pre-Investigational New Drug application (Pre-IND) to the US FDA for a...
September 8, 2021
Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19 September 8, 2021
Adamis Pharmaceuticals Corporation recently announced the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol, an oral antiviral...
August 25, 2021
Noxopharm Phase 1 Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients August 25, 2021
Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda®), a...
August 17, 2021
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate August 17, 2021
Valneva SE recently announced the initiation of a further Phase 3 trial (VLA2001-304) for its inactivated, adjuvanted COVID-19 vaccine candidate,...
August 17, 2021
Dyadic & Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate & C1 Technology for Protein-Based Coronavirus Vaccines & Therapeutics August 17, 2021
Dyadic International, Inc. and Sorrento Therapeutics, Inc. recently announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for….
August 10, 2021
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of COVID-19 Infection & Associated Coagulopathy With rNAPc2 August 10, 2021
ARCA biopharma, Inc. recently announced it has submitted a Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional...
July 8, 2021
Akston Biosciences Announces Positive Phase 1 Data for Second-Generation COVID-19 Vaccine Candidate July 8, 2021
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, recently announced positive results from a 60-subject, open-label, Phase...
July 1, 2021
Atea’s Oral Antiviral Drug Candidate Reduces Viral Replication in Hospitalized Patients With COVID-19 in Phase 2 Interim Analysis July 1, 2021
Atea Pharmaceuticals, Inc. recently announced positive interim results from the global Phase 2 study evaluating AT-527 in hospitalized patients with...
June 16, 2021
Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 & Two Prominent SARS-CoV-2 Variants June 16, 2021
Cocrystal Pharma, Inc. recently announced its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent...
June 3, 2021
Ocugen On Track to Submit EUA Application to US FDA for its COVID-19 Vaccine Candidate June 3, 2021
Ocugen, Inc. recently confirmed its plan to submit its Emergency Use Authorization (EUA) application for COVAXIN to the US FDA...
June 1, 2021
CLINICAL TRIALS - Statistical Challenges in Preserving Integrity of Ongoing Clinical Trials During the COVID-19 Pandemic June 1, 2021
Karen Ooms, Msc, believes the consequences of this pandemic on ongoing clinical trials can be objectively assessed, and with the correct mitigation strategies put in place, study integrity can be preserved, optimizing use of the available resources for both patients and sponsors.
May 6, 2021
Vectura & Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19 May 6, 2021
Vectura Group plc and Inspira Pharmaceuticals Limited recently announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the potential treatment of….
May 6, 2021
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery & Development Programs May 6, 2021
Cocrystal Pharma, Inc. recently announced progress in developing broad-spectrum antiviral drug candidates that target coronaviruses including SARS-CoV-2, the coronavirus that...
